Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Renal Function: later-stage trial registry
2 of 4 indexed Renal Function trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Renal Function: 4 US clinical trials tracked, 2 recruiting.
Renal Function is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Devyser, running 1 of these trials.
Enrollment posture brief
Registry condition renal-function
OPEN 2 | RECR 50% | LATE 1 | EARLY 0 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Renal Function lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Renal Function on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Renal Function is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population
Devyser
NCT07006831
The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function
Auburn University
NCT04334135
The Effect of Therapeutic Hypothermia on Deceased Donor Renal Graft Outcomes - a Randomized Controlled Trial From the Region 5 Donor Management Goals Workgroup
University of California, San Francisco
NCT01680744
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Novartis Pharmaceuticals
NCT01598987
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Renal Function records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Renal Function trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Renal Function page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Renal Function trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Devyser sponsors the most Renal Function trials on record, review their full trial history before evaluating a specific study. See Devyser's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Function condition card totals 4 registered trials; most-linked intervention Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.